Ilumetri (Tildrakizumab)

Tildrakizumab binds selectively to the p19 subunit of interleukin‑23, blocking the cytokine from activating its receptor. This inhibition reduces Th17‑cell activity and downstream inflammatory mediators, leading to decreased skin inflammation characteristic of plaque psoriasis.

The exact dosing schedule for Ilumetri is determined by the prescribing healthcare professional based on the patient’s clinical condition and response. The prescriber decides the amount, frequency and duration of treatment.

The pregnancy safety category for tildrakizumab is unknown. It should only be used during pregnancy or lactation if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and after consultation with a qualified healthcare provider.

To request Ilumetri, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Ilumetri belongs to the IL‑23 inhibitor class, whereas alternatives such as ustekinumab target both IL‑12 and IL‑23, and agents like secukinumab inhibit IL‑17. IL‑23 inhibition offers a more selective approach, which may result in a different safety and efficacy profile compared with broader‑acting biologics.

Ilumetri should be stored in a refrigerator at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside the recommended range.

Ilumetri is given as a subcutaneous injection, typically performed by a healthcare professional. The injection site should be rotated among approved areas such as the abdomen, thigh or upper arm to minimize local irritation.

Serious risks include severe infections (including tuberculosis), allergic reactions such as anaphylaxis, and the potential for malignancies. Patients should be monitored closely for signs of infection, unexpected skin changes or systemic allergic symptoms.

Ilumetri is contraindicated in individuals with known hypersensitivity to tildrakizumab or any excipients. It should also be avoided in patients with active serious infections, those receiving live vaccines, or anyone for whom the risk‑benefit assessment is unfavorable.